Table 8.
Indacaterol 150 μg | Tiotropium 18 μg | Difference | |
Total costs | £4534 | £4781 | −£248 |
Total QALYs | 2.158 | 2.150 | 0.008 |
ICER | Dominanta | ||
Indacaterol 150 μg | Salmeterol 2 × 50 μg | Difference | |
Total costs | £4583 | £4692 | −£110 |
Total QALYs | 2.158 | 2.149 | 0.008 |
ICER | Dominanta | ||
Indacaterol 300 μg | Tiotropium 18 μg | Difference | |
Total costs | £4501 | £4760 | −£259 |
Total QALYs | 2.162 | 2.151 | 0.011 |
ICER | Dominanta |
aDominant = less cost, better outcomes
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-years